Cell-Free Dna Testing Market Analysis By Test Type (Detection Of Abnormal Chromosome Number, Gender Testing, Paternally-Inherited Disorders), By Application (Oncology, Gynecology, Transplantation, Others), By Region, Forecast To 2027

Cell-free DNA Testing: Introduction

Cell-free DNA (cfDNA) are DNA fragments circulating in the blood and are considered valuable biomarkers. The cell-free DNA tests involve prenatal screening for certain disorders caused by an unusually large number of chromosomes. However, the test is not applicable for the detection of all forms of chromosomal disorders. Apart from its use in detecting chromosomal abnormalities in the fetus, the non-invasive screening test can detect graft rejection and identify various mutations in cancer patients. According to industry experts, cfDNA testing could potentially revolutionize the fields of gynecology, oncology, transplantation, and acute infectious diseases.

The prenatal cell-free DNA screening is usually conducted after around ten weeks of pregnancy. The test is done on a sample of the pregnant woman’s blood, which contains some of the genetic material (DNA) formed after pregnancy. Generally, these tests are intended to determine if the fetus is at a higher or lower risk of having a specific abnormal condition. The two predominant types of these screening tests include chorionic villus sampling (CVS) and amniocentesis. If the woman attains a positive result, it implies that a diagnostic test is required to determine the fetus’s condition.

However, there is still a possibility of the baby having a chromosomal disorder or other severe disorders in case of a negative result. As estimated by the Centers for Disease Control and Prevention (CDC), around 6,000 children worldwide are diagnosed with Down syndrome at birth every year. The disease’s incidence rate has augmented by around 30% from 1979 to 2003, added the healthcare agency.

Global Cell-free DNA Testing Market Dynamics:

The growth of the global cell-free DNA testing market is influenced by a plethora of factors. Surging awareness about safe or low-risk obstetric procedures for prenatal screening tests, rising incidence of diseases like chromosomal abnormalities caused by advanced maternal age, increasing incidence of chronic diseases, changing lifestyles leading to life-threatening diseases like diabetes, growing prevalence of cancer, unhealthy food habits, and soaring healthcare expenditure are among the key parameters that are projected to propel the growth of the global cell-free DNA testing market over the forecast timeframe.

However, certain factors pose major threats to the development of the global cell-free DNA testing market. Increasing costs of cfDNA tests, absence of skilled healthcare personnel, non-affordability of these tests in low-income countries, lack of standardization, ethical issues concerned with genetic testing, unclear regulatory guidelines, and unfavorable reimbursement policies are some of the key factors likely to constrain the cell-free DNA testing market growth in the upcoming years.

COVID-19 Impact on the Global Cell-free DNA Testing Market:

Reports and Data’s latest report titled ‘Global Cell-free DNA Testing Market’ offers a vivid description of the current cell-free DNA testing market scenario. The report emphasizes the highly disruptive changes that followed the COVID-19 outbreak. The grappling effects of the COVID-19 pandemic have disturbed the cell-free DNA testing market, causing volatility in prices and demand and interrupting the global supply chains. However, our team of experts believes that the cell-free DNA testing market will regain momentum shortly in the post-COVID scenario. Hence, the report analyzes the effects of COVID-19 on the present and future business landscapes.

Global Cell-free DNA Testing Market: Regional Outlook

The global cell-free fetal DNA testing market comprises several key regions, which include:

· North America (U.S., Mexico, Canada)

· Europe (U.K., Germany, France, Italy, Russia)

· Asia Pacific (India, Japan, China, Korea, Australia, Malaysia, etc.)

· Latin America (Brazil, Argentina, etc.)

· Middle East & Africa (Saudi Arabia, the UAE, South Africa, Egypt, Nigeria, etc.)

The report provides an in-depth understanding of the growth prospects and ongoing trends across various regional segments of the cell-free DNA testing industry. North America has been the leading regional segment, with the largest share, followed by Europe and the Asia Pacific. The growth of the cell-free DNA testing industry in the region can be attributed to a high incidence rate of diseases, an increasing prevalence of aneuploidy (a common chromosomal disorder), advancements in aneuploidy screening, and the region’s evolving healthcare infrastructure. Moreover, several developing countries across the Asia Pacific and the Middle East & Africa hold a huge potential for cell-free DNA testing market growth, as approximated by industry analysts.

Global Cell-free DNA Testing Market: Competitive Overview

The global cell-free DNA testing market is highly consolidated owing to the presence of various top-notch players. The leading companies operating in the sphere are currently focusing on new product launches and numerous other expansion strategies to maintain their leading stance in the cell-free DNA testing market. Furthermore, many new entrants are looking to provide more innovative cfDNA tests, with higher accuracy and lesser turnaround time.

Also, some of the major companies in this industry are acquiring smaller companies at present in order to expand their product portfolios and build on their market presence. For instance, U.S.-based LabCorp acquired molecular technology company, Sequenom, in September 2016, intending to enhance its non-invasive prenatal testing product offerings. Some of the leading players in the cell-free DNA testing market profiled in this report are Laboratory Corporation of America Holdings (LabCorp), Natera, Inc., Guardant Health, F. Hoffmann-La Roche (Roche), Beijing Genomics Institute, Trovagene, Inc., Illumina, Inc., and Biocept, Inc.

Key Report Highlights:

· The report is an exhaustive analysis of the global market trends and investigates the regulatory and investment scenarios of the global cell-free DNA testing market.

· The latest report offers a closer look at a wide array of growth opportunities available in this fast-paced business.

· It involves a detailed pricing analysis based on the extensive geographical segmentation and various product and application types.

· Additionally, it presents a complete overview of the vendor landscape, enumerating the notable companies in this industry to give a clear picture of the intense competition level.

· The report includes an unbiased perspective on the key players’ performance and offers must-have information regarding the initiatives they take to enhance their footprint.

· The report studies the historical, current, as well as estimated market size in terms of value and volume.

Global Cell-free DNA Testing Market Segmentation:

Test type

· Detection of Abnormal Chromosome Number

· Gender Testing

· Paternally Inherited Disorders

Application

· Oncology

· Gynecology

· Transplantation

· NIPT (Non-invasive Prenatal Test)

· Others